English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDesai Sethi Urology Institute (DSUI) Scientific Director Nima Sharifi, M.D., authored an invited commentary in JAMA Network Open related to a new Million Veteran Program study on the HSD3B1 genotype, an allele he helped discover more than 10 years ago.
Tag: prostate cancer
Moncrief Cancer Institute debuts new Mobile Screening Clinic funded by Tarrant County
Moncrief Cancer Institute debuted its new Mobile Screening Clinic prior to the Tarrant County Commissioners Court meeting today. The $1 million, 36-foot cancer screening clinic was funded by Tarrant County through a three-year, $9 million grant awarded to Moncrief Cancer Institute in 2022. Part of the federal funding Tarrant County received through the American Rescue Plan Act (ARPA), the grant enabled Moncrief to expand its comprehensive cancer screening program to more underserved residents in Tarrant County.
The gold standard: Nobel Prize gifted to Tulane University by Dr. Andrew Schally
Former Tulane University researcher Dr. Andrew Schally has donated his Nobel Prize to Tulane’s School of Medicine. Schally won the award in 1977 for identifying the presence of key peptides in the hypothalamus and successfully synthesizing them, research that led to advanced prostate cancer treatment methods.
Sandalwood Oil By-product Prevents Prostate Cancer Development in Mice
Sandalwood oil has been used worldwide for centuries. Now, a study is the first to demonstrate in vivo the chemo-preventive properties of a by-product of the oil in a mouse model. Results show administering alpha-santalol reduced visible prostate tumors, protected the normal tissue, and delayed progression from a precancerous condition to a high-grade form of cancer. These findings are significant because mortality in prostate cancer patients is mainly attributable to advanced stages of the disease.
Prostate Cancer: Prevention, Diagnosis and Treatment
Recent news of two high-profile people has brought awareness to prostate health. Effecting men between ages 45 to 69, when detected early, prostate cancer has the best chance for successful treatment. Aditya Bagrodia, MD, urologic oncologist with UC San Diego…
For Black patients, ‘representation matters’ in evaluating prostate cancer websites
For Black men with prostate cancer, racial representation is a key factor affecting trust in websites offering information on prostate cancer, reports a study in the March issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
Prostate cancer screenings encouraged for Black men as early as 40
New prostate screening guidelines organized by the Prostate Cancer Foundation aim to address the longstanding health disparity in prostate cancer: Black men are diagnosed with and die from prostate cancer at a much higher rate than white men.
New Prostate Cancer Report Card keeps treatment options simple to understand
A new prostate cancer resource – the Prostate Cancer Outcomes Report Card – hopes to make it easier for men and their families to better understand the treatment options and outcomes.
Neuroendocrine prostate cancer could be restored to a state that responds to treatment
It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells.
New Potential Immunotherapies for Pancreatic Cancer
Pancreatic cancer can be a devastating diagnosis due to its extremely aggressive nature and low survival rate.
Urology on the Beach Meeting Highlights Innovative Approaches to Multidisciplinary Care
Renowned urologists from leading academic centers shared their insights and clinical recommendations at Urology on the Beach, a three-day professional conference hosted by the Desai Sethi Urology Institute (DSUI) at the University of Miami Miller School of Medicine.
At the same PSA level, Black men are more likely to have prostate cancer than white men
Findings indicate the importance of earlier and more frequent prostate cancer screening for Black men.
Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer
The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.
High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.
Global Speakers, Cutting-edge Topics, Surgical Theater on Tap for Desai Sethi Urology Institute’s Urology on the Beach 2024
Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will host its second annual, in-person Urology on the Beach meeting, January 19 to 21, 2024, at the Fontainebleau Hotel in Miami Beach.
Winners of the ASTRO-Sumitomo Pharma-Pfizer Alliance new combination therapy challenge announced
The American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
New focal therapies at UTHealth Houston make prostate cancer treatment easier on patients
Tissue-sparing treatments using focal therapy, aimed to avoid side effects like urinary incontinence, are becoming available for prostate cancer patients like Morton McPhail of Texas.
UCSF Health Performs 150th Robotic Focal HIFU Procedure
UCSF Health has performed 150 robotic focal high-intensity focused ultrasound (HIFU) procedures for patients living with prostate cancer, becoming the first on the west coast and the first UC Health System to reach that milestone.
Cancer-causing mutations rewire growth signalling in prostate cancer model
Experts in cell signalling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators.
Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
Prostate Cancer Is More Common Than You Think
The American College of Surgeons (ACS) has partnered with the American Urological Association (AUA) to share vital information about the concerning rise in advanced cases of prostate cancer and how men can protect their health and make the most informed decisions about their healthcare.
Expert Addresses Stigma, Disparities in Prostate Cancer
David M. Golombos, MD, addresses prostate cancer topics
Desai Sethi Urology Institute Researcher Finds “Sneaky Testosterone” Might Signal Worse Outcomes for Men with Prostate Cancer
Findings from the newly published study in The Journal of Clinical Investigation suggest a large proportion of men have testosterone concentrations that are much higher in and around the prostate than traditional blood draws suggest. And this elevated exposure near the prostate increases the risk of poor outcomes after surgical removal of the prostate gland.
September is Prostate Cancer Awareness Month: Know the Warning Signs, When to Get Screened and Important New Treatments
Renowned prostate cancer researcher Dr. Lorelei Mucci is the director of strategic research partnerships at the American Cancer Society. Her role includes leading an ACS initiative called IMPACT, or “Improving Mortality Toward Prostate Cancer Together” to address the alarming negative trends in prostate cancer incidence and disparities. For Prostate Cancer Awareness Month Dr. Mucci reviews the signs and symptoms of prostate cancer, including important information about risk factors, PSA screening, and more.
PSA levels after treatment may not be reliable predictor of survival for patients with prostate cancer
A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient’s long-term overall survival.
Radiation therapy clinical trial at UCLA Health is right approach for Oakland business owner
In June 2021, Bob McCarrick and his wife Stacey headed out to Los Angeles to enroll in the MIRAGE trial and start radiation therapy.
Sylvester Comprehensive Cancer Center Tip Sheet – August 2023
New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .
Detecting risk of metastatic prostate cancer in Black men
To explore prostate cancer disparities, researchers looked to another disorder, diabetes. They conducted a clinical trial and report four biomarkers linked to a higher risk of metastatic prostate cancer in men of West African heritage. They will present their results at ACS Fall 2023.
Renowned Urologic Specialist to Lead UCSF Urology Program
Benjamin N. Breyer, MD, MAS, FACS, a renowned leader in urology and urological surgery, has been appointed chair of the UCSF Department of Urology. Breyer is a urologic surgeon who is internationally known for performing complex urethral and penile reconstruction for urethra stricture and cosmetic disfigurement, male incontinence, male fistula, and surgery for erectile dysfunction.
A step toward treating chemotherapy-resistant prostate cancer
Prostate cancer is resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to die.
In preclinical study, Sylvester researchers target treatment-resistant prostate cancer with oral chemotherapy that works 2 ways
Researchers at Sylvester Comprehensive Cancer Center have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells. The compound – Platin-L – works in two ways, breaking down a process that malignant prostate cancer cells use to fuel their growth, and delivering cisplatin directly into treatment-resistant cancer cells.
A new study validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer
Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.
AI model could help improve outcomes of prostate cancer focal therapy
A new study shows that an artificial intelligence (AI) model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
Study reveals how treatment-resistant prostate cancer provides its own hormonal fuel
A new study in mice, led by researchers at Washington University School of Medicine in St. Louis, explains how prostate cancer senses a drop in testosterone levels due to common anti-hormone therapy and then begins making cholesterol — a necessary precursor to testosterone — to generate its own testosterone to fuel tumor growth. The study also points to a possible drug combination that may stop the cancer from feeding its own growth.
Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer guided by Dana-Farber case study
This case study by Dana-Farber gives evidence-based guidance for how to navigate decision-making for individual patients with metastatic hormone-sensitive prostate cancer.
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
New Study by Sylvester Investigators Indicates Treatment Patterns, Not Genetics, Drive Prostate Cancer Disparities
A large-scale retrospective analysis by researchers with the Sylvester Comprehensive Cancer Center suggests that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestry. The study of almost 13,000 men with advanced prostate cancer, published today in The Lancet Digital Health is one of the most comprehensive studies to date of prostate cancer disparities between men of these ethnicities.
Desai Sethi Urology Institute Presents, Debates and is Recognized at AUA 2023
A banner year for Desai Sethi Urology Institute at urology’s premier meeting, the American Urological Association (AUA) 2023, held April 28-May 1 in Chicago where faculty and researchers led and debated during plenary sessions and presented novel research in topics spanning prostate and bladder cancers to sexual function and robotic surgery.
Moffitt Researchers Develop CAR T Cells that Fight Prostate Cancer in Bone
Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science Advances, a team of Moffitt scientists demonstrates that chimeric antigen receptor T-cell (CAR T) therapy is an effective antitumor approach in mouse models of bone metastatic prostate cancer.
New Prostate Biopsy Procedure Reduces Risk, Improves Accuracy
New UC San Diego Health transperineal prostate biopsy procedure now offered in clinic setting.
Charles Spruck awarded $1.7M to advance “ancient virus” treatment for prostate cancer
With the help of a new grant from the U.S. Department of Defense for more than $1.7 million, Associate Professor Charles Spruck, Ph.D., will advance an innovative therapeutic approach for metastatic prostate cancer. Known as viral mimicry, the approach tricks the body into thinking that it has a viral infection, stimulating an immune response that can help the body fight cancer.
MD Anderson Research Highlights: AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer
In the Nature Cancer study, researchers led by Dana-Farber’s Himisha Beltran, MD, and Martin Bakht, PhD, found that PSMA expression is lower in liver metastases than in other parts of the body, regardless of expression of the androgen receptor. They also found that some tumors that test negative for the AR do express PSMA and that some AR-positive tumors don’t – which led them to look for a control mechanism that doesn’t involve the AR. Their search revealed that the HOXB13 protein as a key regulator of PSMA.
Novel Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
More U.S. Prostate Cancer Patients Choosing Active Surveillance
The number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable-intermediate-risk cancers, according to a study published today in JAMA Internal Medicine.
ENZAMET shows promise as prostate cancer treatment
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
Scientists Pioneer Research to Harness Power of Machine Learning in Prostate Cancer Imaging
Researchers at Sylvester Comprehensive Cancer Center and the Desai Sethi Urology Institute are pioneering research to harness machine learning for the diagnosis and prognosis of prostate cancer, using magnetic resonance imaging (MRI).
Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows
Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind today.